1. Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?

2. Program Overview

3. CNV Subtypes and Clinical Features

4. Identifying and Diagnosing Different CNV Subtypes

5. Treatment Options for CNV Subtypes

6. DRAGON Study Schema: Phase 4, 24-Month, Randomized, Double-Masked, Controlled, Multicenter Study

7. At Baseline, 41.7% of Patients Were Diagnosed With PCV

8. Ranibizumab Treatment Resulted in BCVA Improvements, Regardless of PCV Status

9. Number of Injections Administered Was Similar for Patients With PCV and non-PCV

10. LUMINOUS Trial: Mean VA Outcomes in Global Population: 1-Year Follow-Up Data

11. LUMINOUS Trial: Safety Outcomes in Global Population: 1-Year Follow-Up Data

12. EVEREST II: The Largest Multicenter RCT Conducted for PCV

13. EVEREST II: Treatment Schedule

14. BCVA Change From Baseline to Month 12 and Complete Polyp Regression at Month 12

15. Number of Injections Received in Study Eye Prior to Month 12

16. Number of vPDT/Sham PDT Received in the Study Eye Prior to Month 12

17. PLANET Study: Aflibercept Monotherapy vs Aflibercept Plus PDT in Patients With PCV

18. CATT Study: RAP Subgroup Analysis

19. Importance of Differentiating RAP Lesions

20. Concluding Remarks

21. Abbreviations

22. Abbreviations (cont)